Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) plus ponatinib vs. HCVAD plus dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).

被引：1
|
作者：
Sasaki, Koji
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Daver, Naval Guastad
Kadia, Tapan M.
Konopleva, Marina
Jain, Nitin
Short, Nicholas James
Issa, Ghayas C.
Jeanis, Vicky
Moore, H. Gal
Garris, Rebecca S.
Garcia-Manero, Guillermo
Cortes, Jorge E.
O'Brien, Susan Mary
Jabbour, Elias
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif Irvine, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7025
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Blinatumomab plus ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
    Couturier, Marie-Anne
    Thomas, Xavier
    Raffoux, Emmanuel
    Huguet, Francoise
    Berthon, Celine
    Simand, Celestine
    Gallego-Hernanz, Maria-Pilar
    Hicheri, Yosr
    Berger, Mathilde Hunault
    Saillard, Colombe
    Leguay, Thibaut
    Loiseau, Clemence
    Bene, Marie-Christine
    Chevallier, Patrice
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 620 - 629
  • [22] Outcome of Patients With Chronic Myeloid Leukemia in Lymphoid Blastic Phase and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated With Hyper-CVAD and Dasatinib
    Morita, Kiyomi
    Kantarjian, Hagop M.
    Sasaki, Koji
    Issa, Ghayas C.
    Jain, Nitin
    Konopleva, Marina
    Short, Nicholas J.
    Takahashi, Koichi
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Daver, Naval
    Montalban Bravo, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Jabbour, Elias
    CANCER, 2021, 127 (15) : 2641 - 2647
  • [23] A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL)
    Short, Nicholas James
    Jabbour, Elias
    Jain, Nitin
    Macaron, Walid
    Huang, Xuelin
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Daver, Naval Guastad
    Haddad, Fadi
    Zoghbi, Marianne
    Nasnas, Cedric Christophe
    Nasr, Lewis Fady
    Mayor, Ejiroghene
    Deen, Wuliamatu
    Thankachan, Jennifer
    Loiselle, Christopher
    Garris, Rebecca
    Konopleva, Marina
    Ravandi, Farhad
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH plus ) Chronic Myeloid Leukemia (CML) or PH plus Acute Lymphoblastic Leukemia (ALL): a Pharmacokinetic Study
    Hijiya, Nobuko
    Zwaan, C. Michel
    Rizzari, Carmelo
    Foa, Roberto
    Abbink, Floor
    Lancaster, Donna
    Landman-Parker, Judith
    Millot, Frederic
    Moppett, John
    Nelken, Brigitte
    Ducassou, Stephane
    Putti, Maria Caterina
    Tian, Xianbin
    Sinclair, Karen
    Santanastasio, Helene
    Buchbinder, Aby
    Kearns, Pamela
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S34 - S34
  • [25] Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute L phoblastic Leukemia (ALL)
    Jabbour, Elias
    Kantarjian, Hagop
    Thomas, Deborah A.
    Ravandi, Farhad
    Cortes, Jorge E.
    Faderl, Stefan H.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Garris, Rebecca
    Hillary, Prescott
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    O'Brien, Susan
    BLOOD, 2013, 122 (21)
  • [26] Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center
    Othman, Tamer
    Moskoff, Benjamin N.
    Ho, Gwendolyn
    Tenold, Matthew E.
    Azenkot, Tali
    Krackeler, Margaret L.
    Fisch, Samantha C.
    Potter, Laura A.
    Kaesberg, Paul R.
    Welborn, Jeanna L.
    Wun, Ted
    Esteghamat, Naseem S.
    Hoeg, Rasmus T.
    Rosenberg, Aaron S.
    Abedi, Mehrdad
    Tuscano, Joseph M.
    Jonas, Brian A.
    LEUKEMIA RESEARCH, 2022, 119
  • [27] Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib
    Ottmann, Oliver G.
    Larson, Richard A.
    Kantarjian, Hagop M.
    le Coutre, Philipp
    Baccarani, Michele
    Haque, Ariful
    Gallagher, Neil
    Giles, Francis
    BLOOD, 2007, 110 (11) : 828A - 828A
  • [28] Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults
    Oh, Iekuni
    Hatano, Kaoru
    Ikeda, Takashi
    Toda, Yumiko
    Minakata, Daisuke
    Kawaguchi, Shinichiro
    Morita, Kaoru
    Yamamoto, Chihiro
    Ashizawa, Masahiro
    Sato, Kazuya
    Kameda, Kazuaki
    Gomyo, Ayumi
    Misaki, Yukiko
    Kawamura, Shunto
    Kimura, Shunichi
    Kobayashi, Hiroyuki
    Sato, Hiroyuki
    Nakasone, Hideki
    Ohmine, Ken
    Fujiwara, Shinichiro
    Kako, Shinichi
    Kanda, Yoshinobu
    LEUKEMIA RESEARCH, 2024, 137
  • [29] SAFETY AND TOLERABILITY OF DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH plus ALL): POOLED ANALYSIS OF OVER 2400 PATIENTS
    Saglio, G.
    le Coutre, P.
    Cortes, J.
    Mayer, J.
    Rowlings, P.
    Subar, M.
    Preston, J.
    Shah, N.
    HAEMATOLOGICA, 2014, 99 : 329 - 329
  • [30] Dasatinib population pharmacokinetics in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ph plus all)
    Dai, Guowei
    Roy, Amit
    Mandava, Mohan
    Blackwood-Chirchir, Anne
    Luo, Roger
    Wu, Chiyuan
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
12345